Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.55 |
| ▸ | PPARG | P37231 | 10/20 | 0.55 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.52 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15564842 | 1.00 | PPARA (0.55) | PPARAPPARGGSTP1GSTM2PPARD | |
| SCHEMBL7977007 | 0.88 | GSTP1 (0.56) | PPARAPPARGGSTP1GSTM2PPARD | |
| SCHEMBL15956153 | 0.88 | GSTP1 (0.56) | PPARAPPARGGSTP1GSTM2PPARD | |
| SCHEMBL9065305 | 0.83 | ALDH1A1 (0.43) | ACE | |
| SCHEMBL15564586 | 0.81 | PPARA (0.56) | PPARAPPARGPPARDACEIDO1 | |
| SCHEMBL15564582 | 0.81 | PPARA (0.56) | PPARAPPARGPPARDACEIDO1 | |
| SCHEMBL22687231 | 0.80 | PPARA (0.51) | PPARAPPARGGSTP1GSTM2PPARD | |
| SCHEMBL22687233 | 0.80 | PPARA (0.51) | PPARAPPARGGSTP1GSTM2PPARD | |
| SCHEMBL1999989 | 0.80 | GSTP1 (0.55) | PPARAPPARGGSTP1GSTM2PPARD | |
| SCHEMBL1997073 | 0.79 | PPARG (0.48) | PPARAPPARGGSTP1GSTM2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2882725-A1 | SUBSTITUTED HETERO-AZEPINONES | F. Hoffmann-La Roche AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | CCNY, CCNE1, CCND3 | PPARA 4177/4885PPARG 3108/4885GSTP1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.